|Articles|March 21, 2023

Catching a Common Cold Gives Children COVID-19 Immunity

Author(s)Nina Cosdon

Exposure to a common seasonal coronavirus stimulates a memory T cell response that protects children against COVID-19. However, this immune response peaks at age 6.

Throughout the COVID-19 pandemic, children have experienced less severe disease progression than adults. Some investigators hypothesize this is due to common colds helping children generate memory CD4+ T cells that provide a level of immunity against COVID-19.

A team of researchers from the Karolinska Institutet in Sweden wanted to determine whether contracting OC43, 1 of the 4 coronaviruses responsible for seasonal colds, stimulates a T cell response that protects children against COVID-19.

The investigators assessed humoral and cellular immune responses against OC43 and COVID-19 in children and adults who had never been exposed to COVID-19. They collected 48 blood samples from 2- and 6-year-old children, and 94 samples from adults aged 26-83 years. As a control, the study also included blood samples from 58 individuals who had recently recovered from COVID-19.

The investigators found preexisting COVID-19 reactive CD4+ T cell responses targeting spike, nucleocapsid, and membrane were closely linked to the frequency of OC43-specific memory CD4+ T cells in childhood.

This is evidence that functional cross-reactive memory CD4+ T cell immunity against COVID-19 is established during early childhood, similar to early seroconversion with seasonal human coronavirus OC43.

The study authors wrote that compared to other viruses, the high OC43 seroprevalence at age 2 suggests memory responses to coronaviruses develop at a young age. However, unlike other viruses, these OC43-specific antibodies did not increase further with age. “These reactions are especially strong early in life and grow much weaker as we get older,” said Annika Karlsson, a study author and research group leader at the Karolinska Institutet Department of Laboratory Medicine.

The robustness of the memory CD4+ T cell responses peaked at age 6 and then declined with age. The investigators concluded that these age-dependent qualitative differences in preexisting COVID-19-reactive T cell responses may reflect an individual’s ability to control coronavirus infections and mount an immune response to vaccination.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.